C

Clinilabs Drug Development Corporation | Eatontown, NJ

Research site

(Unclaimed)

Location

4 Industrial Way West 2nd Floor, Eatontown, New Jersey, United States of America

Site insights

Top conditions

Top treatments

INZ-701

GATE-101

Aroxybutynin

CYB003

ANC-501

Psilocybin Analog

Atomoxetine

Heroin

OXY

IXT-m200

Parent organization

This site is a part of Clinilabs Drug Development Corporation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 15 total trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Defici...

Enrolling

Arterial Calcification

Autosomal Recessive Hypophosphatemic Rickets Type 2

Drug: INZ-701

An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia (Jive)

This is an open-label extension (OLE) study designed to evaluate the long-term safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), an...

Invitation-only

Friedreich Ataxia

Biological: CTI-1601

Locations recently updated

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine